The comparison of the surgical outcome of 27-gauge pars plana vitrectomy for primary rhegmatogenous retinal detachment between air and SF6 gas tamponade
The comparison of the surgical outcome of 27-gauge pars plana vitrectomy for primary rhegmatogenous retinal detachment between air and SF6 gas tamponade
复制标题
DOI：
10.1038/s41433-019-0726-2
复制
发表时间：
2020-02-01
期刊：
影响因子：
3.9
通讯作者：
Nakamura, Makoto
中科院分区：
文献类型：
--
作者：
Tetsumoto, Akira;Imai, Hisanori;Nakamura, Makoto
学习目标 完成本活动后，参与者将能够： 根据一项回顾性、观察性和连续性研究，比较 27GPPV 中空气和 20% SF6 填塞在 RRD 中的解剖成功率。根据一项回顾性、观察性和连续性研究，比较 27GPPV 中空气和 20% SF6 填充治疗 RRD 的 12 个月随访期间的视觉结果和眼压变化。根据一项回顾性、观察性连续研究，比较 27GPPV 中空气和 20% SF6 填塞治疗 RRD 的 12 个月随访期间并发症的类型和频率，并描述有关手术结果的其他临床影响。认证声明 为了支持改善患者护理，这项活动由 Medscape, LLC 和 Springer Nature 策划和实施。 Medscape, LLC 获得继续医学教育认证委员会 (ACCME)、药学教育认证委员会 (ACPE) 和美国护士资格认证中心 (ANCC) 联合认证，为医疗团队提供继续教育。 Medscape, LLC 指定这项基于期刊的 CME 活动最多可获得 1.0 AMA PRA 类别 1 学分(TM)。医生只能根据其参与活动的程度获得相应的荣誉。学时 1.0 发布日期：2019 年 12 月 20 日 到期日期：2020 年 12 月 20 日 测试后链接：作者/编辑披露信息 A.T.未披露任何相关财务关系。你好。已披露以下相关财务关系： 获得来自爱尔康日本公司的临床研究资助。 M.H.未披露任何相关财务关系。 K.O.未披露任何相关财务关系。 W.M. 没有透露任何相关的财务关系。是。未披露任何相关财务关系。 MN.已披露以下相关财务关系： 获得来自爱尔康日本公司的临床研究资助；大冢制药。 Sobha Sivaprasad（编辑）披露了以下相关财务关系： 担任 Allergan, Inc. 的顾问或顾问；拜耳公司；勃林格殷格翰制药公司；海德堡制药有限公司；光电；罗氏。曾担任以下公司的发言人或发言人局成员：Allergan, Inc.；拜耳公司；诺华制药公司；光学。获得艾尔建 (Allergan), Inc. 的临床研究资助；拜耳公司；勃林格殷格翰制药公司；诺华制药公司；光学。 《CME》杂志作者披露信息 Laurie Barclay 未披露相关财务关系。 目的 比较空气和 20% 六氟化硫 (SF6) 填充在 27 号玻璃体切除术 (27GPPV) 中治疗孔源性视网膜脱离 (RRD) 的手术结果。方法 回顾性、观察性、连续性研究。所有接受 27GPPV 治疗 RRD 的患者被分为两组。 A 组包括接受 20% SF6 气体填塞的患者。 B 组包括接受空气填塞的患者。研究并比较了各组之间的解剖成功率、视力结果以及并发症的类型和频率。所有患者术后均随访12个月。结果 共纳入70只眼（A组：35只眼，B组：35只眼）。 A组17眼和B组13眼出现RRD伴上视网膜裂孔，A组14眼和B组19眼出现RRD伴下视网膜裂孔。各组之间的术前人口统计数据没有统计学差异。 A组初始和最终解剖成功率分别为97.1%和100%，B组分别为94.3%和100%。各组之间的成功率没有统计学差异（p = 1）。术后12个月的最佳矫正视力（BCVA）（logMAR）A组为-0.02 +/- 0.14，B组为-0.03 +/- 0.27。各组之间的BCVA没有统计学差异（p = 0.27）。结论 在 27GPPV 治疗 RRD 中，无论视网膜裂孔位置如何，空气填塞的手术结果均不逊色于 20% SF6 填塞。
Learning objectives Upon completion of this activity, participants will be able to: Compare anatomical success rate between air and 20% SF6 tamponade in 27GPPV for RRD, according to a retrospective, observational, and consecutive study. Compare visual outcomes and changes in intraocular pressure during 12-month follow-up between air and 20% SF6 tamponade in 27GPPV for RRD, according to a retrospective, observational, and consecutive study. Compare type and frequency of complications during 12-month follow-up between air and 20% SF6 tamponade in 27GPPV for RRD, according to a retrospective, observational, consecutive study, and describe other clinical implications regarding surgical outcomes. Accreditation Statements In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)(TM). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit Hours 1.0 Release date: 20 December 2019 Expiration date: 20 December 2020 Post-test link: Authors/Editors disclosure information A.T. has disclosed no relevant financial relationships. H.I. has disclosed the following relevant financial relationships: received grants for clinical research from: Alcon Japan. M.H. has disclosed no relevant financial relationships. K.O. has disclosed no relevant financial relationships. W. M. has disclosed no relevant financial relationships. A.M. has disclosed no relevant financial relationships. M.N. has disclosed the following relevant financial relationships: received grants for clinical research from: Alcon Japan; Otsuka Pharmaceuticals. Sobha Sivaprasad (Editor) has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Optos; Roche. Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos. Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos. Journal CME author disclosure information Laurie Barclay has disclosed no relevant financial relationships.Objectives To compare the surgical results between air and 20% sulfur hexafluoride (SF6) tamponade in 27-gauge pars plana vitrectomy (27GPPV) for rhegmatogenous retinal detachment (RRD). Methods A retrospective, observational, and consecutive study. All patients underwent 27GPPV for RRD were divided into two groups. Group A comprised patients who underwent 20% SF6 gas tamponade. Group B comprised patients who underwent air tamponade. The anatomical success rate, visual outcome, and the type and frequency of complications were investigated and compared between the groups. All patients were followed-up for 12 months after surgery. Results Seventy eyes were enrolled (Group A: 35 eyes, Group B: 35 eyes). Seventeen eyes in Group A and 13 eyes in Group B had RRD with superior retinal breaks, while 14 eyes in Group A and 19 eyes in Group B had RRD with inferior retinal breaks. There was no statistically difference in preoperative demographic date between the groups. The initial and final anatomical success rates were 97.1% and 100% in Group A and 94.3% and 100% in Group B, respectively. The success rates between the groups were not statistically different (p = 1). The best corrected visual acuity (BCVA) (logMAR) at 12 months after surgery was -0.02 +/- 0.14 in Group A and -0.03 +/- 0.27 in Group B. The BCVA between the groups was not statistically different (p = 0.27). Conclusions The surgical results of air tamponade were not inferior to 20% SF6 tamponade in 27GPPV for RRD irrespective of retinal break locations in the present cohort.